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Abstract
Background: Neonatal blood, obtained from a heel stick and stored dry on paper cards, has been
the standard for birth defects screening for 50 years. Such dried blood samples are used, primarily,
for analysis of small-molecule analytes. More recently, the DNA complement of such dried blood
cards has been used for targeted genetic testing, such as for single nucleotide polymorphism in
cystic fibrosis. Expansion of such testing to include polygenic traits, and perhaps whole genome
scanning, has been discussed as a formal possibility. However, until now the amount of DNA that
might be obtained from such dried blood cards has been limiting, due to inefficient DNA recovery
technology.
Results: A new technology is employed for efficient DNA release from a standard neonatal blood
card. Using standard Guthrie cards, stored an average of ten years post-collection, about 1/40th of
the air-dried neonatal blood specimen (two 3 mm punches) was processed to obtain DNA that was
sufficient in mass and quality for direct use in microarray-based whole genome scanning. Using that
same DNA release technology, it is also shown that approximately 1/250th of the original purified
DNA (about 1 ng) could be subjected to whole genome amplification, thus yielding an additional
microgram of amplified DNA product. That amplified DNA product was then used in microarray
analysis and yielded statistical concordance of 99% or greater to the primary, unamplified DNA
sample.
Conclusion: Together, these data suggest that DNA obtained from less than 10% of a standard
neonatal blood specimen, stored dry for several years on a Guthrie card, can support a program
of genome-wide neonatal genetic testing.
Background
Dried neonatal blood, stored and processed on filter
paper, has been the standard for neonatal screening for 50
years [1]. The ordinary use of neonatal blood is based
upon the excision of blood spot punches, typically 3 mm-
6 mm in diameter, followed by physical or biochemical
analysis of serum analytes released from the punch by
soaking in alcohol or water [2]. More recently, dried
blood spots have been used to screen for heritable traits at
the DNA level, typically traits such as cystic fibrosis and
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the thalassemias, and other traits that are readily assayed
by PCR tests [3,4].
In 2005, based on recent advances made in highly parallel
microarray technology, geneticists at March of Dimes pro-
posed that we may be entering an era where the DNA
complement of such dried blood spots might be suffi-
cient, in terms of quantity and quality, to support
genome-wide analysis of complex heritable traits, thereby
leapfrogging the limits of single-gene analysis[5].
In spite of the exciting prospects implied by that 2005
review, relatively little work has been published in the
intervening three years to validate such genome-scale neo-
natal screening [6,7]. Microarray technology has
improved significantly in that period, in terms of dimin-
ished cost and sample requirement, and has yielded
increased data density and quality [8]. However, such
genome-scale microarray analysis continues to require an
input DNA mass (about 250 ng) that is about 100 times
larger than required for simple PCR testing; requires DNA
that is double stranded; and requires DNA with a length-
span that is about 5 times longer than required for most
PCR reactions. Thus, going forward, it is suggested here
that a major technical barrier to the adoption of genome-
wide microarray technology may not be the microarray
technology per se, but instead, may be the quantity and
quality of DNA that can be usefully recovered from an
ordinary air-dried neonatal blood specimen.
The importance of DNA recovery from such Guthrie cards
is discussed at length in a recent comparative study by Sjo-
holm and colleagues [9]. They have compared a number
of commercially available kits and procedures for DNA
recovery from Guthrie cards and have show that only
about 15%–25% of the total DNA complement can be
recovered. They have measured DNA recovery from dried
blood spots stored for up to 26 years, and have shown
that, on standard 3 mm punches from such cards, DNA
yields (with the best available technology) are only about
30 ng per punch.
However, in spite of the relatively low yields, Sjoholm
have shown that the small amount of DNA obtained
remains an excellent substrate for whole genome amplifi-
cation, and relatively complex multiplex SNP analysis [9].
However, for genome wide scanning methods such as
microarray analysis (which require at least 250 ng of input
DNA) the relatively low DNA recoveries, obtained by Sjo-
holm, would require extraction and pooling of as many as
eight 3 mm punches: a value that is difficult to reconcile
for such rare specimens.
Generally similar results have been obtained by Mas (10)
in a study of dried blood spots stored on treated filter
paper matrices such as Whatman FTA or IsoCode,
employing the manufacturer's extraction method. In that
study, about 25% recovery was obtained in a single extrac-
tion, to yield up to 150 ng of single stranded DNA as a 200
uL solution, per 40 uL of adult human blood input [10].
As for the by Sjoholm, the DNA obtained by Mas et. al.
could be used effectively for multiplex PCR and for whole
genome amplification, but as the authors correctly noted,
might be too dilute too support more complex studies
such as genome wide microarray analysis. Moreover, since
the DNA extraction procedures employed by Mas yielded
denatured DNA, the product of such extractions would
not be applicable to methods such as Affymetrix microar-
rays, which require that the DNA substrate remains in a
native, double stranded state prior to analysis.
Here, we describe the use of a new technology, referred to
as GenSolve™, originally developed as a high-efficiency
method to recover native DNA from blood spots on
chemically treated FTA filter paper [11] but used here to
recover DNA from neonatal blood spots on standard
Guthrie cards collected from 1991 to 2003 as part of the
California Birth Defects Monitoring Program. The Gen-
Solve technology was used in combination with standard
DNA purification, followed by analysis on the Illumina
610 bead array microarray platform, which interrogates
about 610,000 sites of human SNP variation in parallel
[12].
Although the Illumina 610 chip does not contain content
that was developed specifically for neonatal screening, the
scale of the analysis performed on the Illumina 610 chip
can be viewed as a technical surrogate for any large panel
of genome-wide SNP testing that could be developed as a
screening tool. For the immediate future, neonatal screen-
ing will likely continue to employ biochemical analysis
mediated by tandem mass spectrometry and related meth-
ods, to which genetic testing will be added, in parallel.
Typically, only a small fraction of a dried neonatal sample
will be available for microarray or microarray-like genetic
analysis. Thus, the work described here is focused on
microarray testing using DNA obtained from only two 3
mm diameter Guthrie card punches, roughly 1/40th of the
blood ordinarily collected from a neonate, on a standard
5-spot Whatman 903 Guthrie card [13].
Results and discussion
DNA recovery
Table 1 presents the purified DNA recovery from 24 dried
neonatal blood samples obtained from the California
Birth Defects Monitoring Program. The average pooled
DNA recovery from two identical 3 mm punches, via the
GenSolve technology, was measured to be 260 ng +/- 70
ng. Based on the yields obtained by Sjoholm (9) the data
presented in Table 1 suggest that the observed DNA recov-
ery from paired 3 mm punches (260 ng) obtained with
GenSolve is approximately 4 times greater than would beBMC Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2156/10/38
Page 3 of 8
(page number not for citation purposes)
Table 1: DNA Recovery from Two 3 mm Guthrie Card Punches
sample ID Yield (ng) Conc (ng/uL) Specimen Name Collection Date
1 261.7 26 530011 1995
2 203.37 20 529979 1995
3 162.33 16 529969 2003
4 312.9 31 529943 2003
5 380.43 38 529844 1994
6 212.16 21 529895 1994
7 319.9 32 520908 2001
8 188.41 19 529809 2001
9 246.88 65 MOD881 1993
10 244.55 65 MOD892 1993
11 225.47 23 529874 2003
12 131.31 13 529810 2003
13 391.96 50 MOD919 1998
14 367.67 48 MOD937 1998
15 161.23 16 529852 2000
16 264.59 26 529906 2000
17 255.67 57 MOD920 1995
18 226.43 65 MOD975 1995
19 268.02 69 MOD986 1995
20 234.94 53 MOD001 1995
21 350.78 35 530127 1995
22 339.53 34 530128 1991
23 224.1 22 529236 1992
24 274.61 27 529237 1997
overall average <260 ng> <26 ng/uL> <1997>
Microarray samples <280 ng> <59 ng/uL> <1995>
DNA concentration was measured via PicoGreen analysis. Samples in red refer to those specimens used for microarray analysis, based on the 
requirement that their DNA concentration exceed 50 ng/uL to accommodate Illumina hybridization chemistry. Notice that the average DNA yield 
(in nanograms) for the 8 specimens used for microarray analysis and their average age did not deviate significantly from the average of all 24. 
However, due to volume variability in the final concentrated DNA sample, the mass concentration of the 8 specimens used for microarray analysis 
(59 ng/uL) was approximately twice that of the average over the entire set of twentyfour (26 ng/uL).
Samples to be used for Illumina 610 Microarrays, without prior WGA Figure 1
Samples to be used for Illumina 610 Microarrays, without prior WGA. Samples were applied at 100 ng per well and run 
on an Invitrogen 0.8% agarose E-gel for 30 minutes, and visualized by ethidium bromide staining.
1: 1kb Apex ladder 
2:  529881 
3:  529892 
4:  529919 
5:  529937 
6:  529920 
7:  529975   
8:  520986   
9:  530001 
10: 2.5kb Apex ladder 
11: 100ng Roche DNA BMC Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2156/10/38
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predicted from previously studied methods (60 ng).
Assuming 0.6 uL of dried blood wetting per mm2 [14] the
average yield per two such 3 mm diameter punches, dis-
tributed over 14 mm2, corresponds to an average DNA
recovery of 19 ng/mm2, averaged over the full 24 sample
set, and an average DNA recovery of 30 ng/uL relative to
the original fluid blood specimen, which is near to the
value expected for 100% DNA recovery.
DNA Quality
The length of the DNA obtained was estimated using
0.8% agarose gel electrophoresis. As seen in Figure 1, 100
ng of each sample chosen for microarray analysis (lanes
2–9) was compared to 100 ng of very high molecular
weight Roche DNA control (lane 11). In all cases, the
Guthrie card DNA samples are present as a single col-
lapsed band which migrates in the 40 kb range, relative to
external size standards (lanes 1 & 10). Similar analysis has
been performed on the remaining 15 samples, not used
for microarray analysis (Figures 2 &3). Taken together
these data indicate that the majority of the DNA isolated
from these Guthrie cards is longer than 40 kb.
Whole Genome Amplification
To determine if the DNA extracted from these Guthrie
card samples might be extended to a larger number of
DNA tests, PCR-based whole genome amplification was
performed on the 8 samples to be analyzed on the Illu-
mina 610 microarray platform. The Sigma-Rubicon
amplification technology was employed [15] which, as a
necessary first-step in the process, induces chemical shear-
ing of the DNA template to about 200 bp-1000 bp, which
is followed by thermal cycling to affect a 100–1000 fold
mass amplification. The yield of those reactions is sum-
marized in Table 2. Beginning with 1 ng of Guthrie card
DNA, a final product yield of 1 ug-2 ug is obtained in all
cases. Since only about 1/250th of the original purified
DNA sample was used in these reactions, the data of Table
2 illustrate that, when coupled to Sigma-Rubicon WGA,
the DNA content of two 3 mm dried blood spots could
(with pooling) be amplified to a final yield of greater than
200 ug, thus enabling a broader range of applied genetics
applications. As seen in Figure 4, 100 ng of the amplified
product is characterized by the expected size distribution
range from 200 bp to about 1,000 bp on a 1.4% agarose
gel. It is interesting to note that this Guthrie card DNA,
used at 1 ng, produced, as expected, roughly 5–10 fold less
amplified product than a highly purified DNA reference
sample at 10 ng of template input, suggesting that the
Guthrie card DNA behaved as a similar amplification sub-
strate.
Illumina 610 Microarray Analysis
Eight primary DNA isolates (underlined in Table 1) and
the corresponding whole genome amplified products of
those eight (Table 2) were used for microarray analysis on
the Illumina 610 microarray platform. Although the over-
all DNA yield from these eight samples (280 ng) was only
marginally higher than the average over the entire set of
24 (260 ng) the eight which were chosen for microarray
analysis all presented with a mass concentration greater
than 50 ng/uL which is the minimum required for the
Illumina platform. That variability in concentration, but
not total yield, is due to the difficulty in controlling the
volume obtained during the final Microcon concentration
step. It should be noted that the average collection date of
the eight specimens chosen (1995) is not significantly dif-
ferent than the average of the full set of 24 (1997).
The quality of those DNA samples as a substrate for micro-
array analysis has been summarized as the SNP call rate,
which is a measure of the fraction of 610,000 SNP assays
Samples not used for Illumina 610 Microarrays, without prior WGA Figure 2
Samples not used for Illumina 610 Microarrays, without prior WGA. Samples were applied at 100 ng per well and run 
on an Invitrogen 0.8% agarose E-gel for 30 minutes, and visualized by ethidium bromide staining.
1: 100bp Apex ladder 
2:  530011 
3:  529979 
4:  529969 
5:  529943 
6:  529844 
7:  529895 
8:  520908 
9:  529809 
10: 1kb Apex ladder 
11: 100ng Roche DNA BMC Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2156/10/38
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performed by the array. It is generally accepted that SNP
call rates in excess of 90% are acceptable, while those in
excess of 94% are considered to be high quality, and those
in excess of 99% are considered to be very high quality
[16]. As seen in Table 3, all eight of the primary DNA iso-
lates gave SNP call rates greater than 99%. Microarray data
quality derived from 1 ng of the identical sample, but
whole genome amplified prior to microarray analysis,
showed uniform diminishment of microarray SNP call
rate to 94% or greater, which may be attributable to the
(expected) reduction of template length incurred during
amplification (see Figure 4).
An alternative, more rigorous assessment of quality for
those samples was next obtained on the Illumina 610
microarray platform. Microarray data from unamplified
and the corresponding WGA-amplified samples were
compared, pair-wise, using Illumina statistical software
[17]. These data are presented in Table 4, and indicate that
among the approximately 600,000 SNP loci that were
measured in both sample types, concordance between
measured data was in excess of 99%, thus illustrating that
the WGA-amplified material presents an accurate reflec-
tion of genetic variation in the sample tested.
Conclusion
We have demonstrated that high quality DNA can be
obtained from a standard neonatal blood screening card,
stored dry for at least 10 years. In at least 1/2 of the sam-
ples tested, about 1/40th of a standard dried blood sample
on Guthrie card (two 3 mm punches) is sufficient for
genome wide microarray analysis. The data also suggest
that, when that primary DNA is amplified via the Sigma-
Rubicon method, as little as 1 ng of the recovered DNA
can be used for genome wide microarray analysis. Thus,
these data suggest that, for other methods of genome-
Samples not used for Illumina 610 Microarrays, without prior WGA Figure 3
Samples not used for Illumina 610 Microarrays, without prior WGA. Samples were applied at 100 ng per well and run 
on an Invitrogen 0.8% agarose E-gel for 30 minutes, and visualized by ethidium bromide staining.
1: 100bp Apex ladder 
2:  529874 
3:  529810 
4:  529852 
5:  529906 
6:  529236 
7:  529237  
8:  1kb Apex ladder 
9:  100ng Roche DNA 
Table 2: Whole Genome Amplification, from 1 ng of DNA, Recovered from Two 3 mm Guthrie Card Punches
Sample ID Specimen Name
(1 ng input)
260 280 260/280 ug/ul Total
(ug)
9 WGA 881 0.04 0.03 1.78 0.03 1.19
10 WGA 892 0.05 0.03 1.68 0.03 1.38
13 WGA 919 0.06 0.03 1.94 0.04 1.67
14 WGA 937 0.08 0.05 1.79 0.05 2.27
17 WGA 920 0.04 0.03 1.79 0.03 1.19
18 WGA 975 0.06 0.04 1.75 0.04 1.67
19 WGA 986 0.06 0.04 1.68 0.04 1.73
20 WGA 001 0.05 0.03 1.65 0.03 1.46
Human gDNA CTL (10 ng input) 0.39 0.2 1.96 0.23 10.4
Blank 0.01 0.01 1.43 0.01 0.3
DNA concentration of the amplified product was measured by NanoDrop AnalysisBMC Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2156/10/38
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wide scanning that require multiple-microgram quantities
of DNA, only a few nanograms of the primary DNA isolate
might be similarly amplified and pooled for use.
The total DNA yields were at or above the useful microar-
ray range (250 ng) for about 2/3 of the Guthrie card spec-
imens tested, whereas the remaining 1/3 of the samples
yielded DNA in the range from 130 ng to 250 ng. Thus,
the data illustrate that the larger surface area, and hence
greater amount of dried blood specimen obtained from
three 3 mm punches or a single 6 mm punch might be a
more dependable sample source, and might produce
enough DNA from microarray analysis from most neona-
tal specimens. Since 6 mm Guthrie card punching is rou-
tine in the current practice of automated, high throughput
neonatal screening, the data here suggest that a standard 6
mm Guthrie card punch could (as first envisioned in
2005) might become the basis for genome-wide neonatal
testing. Confirmation of that prediction is ongoing.
Methods
Neonatal Blood Specimens
A series of standard dried neonatal blood specimens were
obtained on standard Whatman 903 "Guthrie" cards (GE-
Whatman Corporation) over the period from 1991 to
2003 by the California Birth Defects Monitoring Program
as part of a larger genetic investigation of risk factors of
birth defects. Use of the human specimens for the pur-
poses of the main study and the current sub-study was
approved by the California Committee for the Protection
Samples to be used for Illumina 610 Microarrays, subsequent to WGA Figure 4
Samples to be used for Illumina 610 Microarrays, subsequent to WGA. Samples were applied at 100 ng per well and 
run on an Invitrogen 1.2% agarose E-gel for 30 minutes, and visualized by ethidium bromide staining.
1: 1kb Apex ladder 
2:  529881 
3:  529892 
4:  529919 
5:  529937 
6:  529920 
7:  529975   
8:  520986   
9:  530001 
10: 2.5kb Apex ladder 
11: 100ng Roche DNA 
Table 3: Illumina 610 Microarray Data: QC Analysis On DNA Obtained from Two 3 mm Guthrie Card Punches
Specimen Name No Calls Calls Total Call Rate (%)
Primary DNA Isolate
MOD 881 1484 591008 592492 99.75
MOD 892 1581 590911 592492 99.73
MOD 919 1502 590990 592492 99.75
MOD 937 1607 590885 592492 99.73
MOD 920 2524 589968 592492 99.57
MOD 975 2840 589652 592492 99.52
MOD 986 2432 590060 592492 99.59
MOD 001 3240 589252 592492 99.45
Corresponding Whole Genome Amplified DNA
WGA 881 31699 560793 592492 94.65
WGA 892 19207 573285 592492 96.76
WGA 919 27928 564564 592492 95.29
WGA 937 17094 575398 592492 97.11
WGA 920 27680 564812 592492 95.33
WGA 975 27080 565412 592492 95.43
WGA 986 22501 569991 592492 96.20
WGA 001 34458 558034 592492 94.18
SNP call rates were determined by Illlumina BeadArray analysis.BMC Genetics 2009, 10:38 http://www.biomedcentral.com/1471-2156/10/38
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of Human Subjects. Duplicate aliquots were excised for
analysis by hole-punching with a standard 3 mm Harris
punch. Both were then transferred to a 1.5 ml microfuge
tube for subsequent processing.
DNA Extraction from Neonatal Blood Cards
DNA is a large polymer chain compared to the size of the
pores of the Guthrie card filter paper, thus restricting DNA
release from dried blood upon rehydration. The tradi-
tional methods to facilitate DNA release from Guthrie
card filter paper require denaturation of the DNA using a
strong alkaline compound or by heating (10) thus com-
promising the physical and chemical integrity of the
stored DNA and rendering the DNA unusable for micro-
array analysis, which requires that DNA be recovered in its
native, double stranded form. Here we have employed a
simple technology, "GenSolve™", that allows genomic
DNA in its native, double stranded form to be released
from dried blood on filter paper, concurrent with ordi-
nary protease treatment of the blood. The manufacturer's
standard protocol was employed as described for process-
ing of treated FTA paper (GenVault Corporation). Briefly,
two 3 mm punches from a Guthrie card were pooled and
incubated for one hour at 65C, with shaking, in a standard
1.5 ml microfuge tube, in the presence of 400 ml of Gen-
Solve Solution A, 100 uL of Savinase solution, in 1%
LiDS, overall.
Subsequent to inactivation with GenSolve Solution B, the
resulting solution phase was isolated by centrifugation
through a spin basket, then loaded directly onto a Qiagen
QiaAmp Mini column for DNA purification (Qiagen Cor-
poration). The resulting DNA eluate was concentrated to
5–10 uL on a Microcon Y100 membrane (Millipore Cor-
poration), and then transferred to a 0.6 ml microfuge tube
for storage at 4C until use in Illumina 610 microarray
analysis. Since a final volume in the 5 uL–10 uL range is
difficult to standardize on a Microcon filter, we have
observed that the final DNA concentrations obtained (as
in Table 1) were more variable than the total DNA yields,
due to variability in the final sample volume.
DNA Quality Analysis
The purified DNA complement from Guthrie cards was
quantified by PicoGreen analysis (Invitrogen Corpora-
tion) relative to both external and internal standards and
recorded as both total yield (nanograms) and DNA mass
concentration (ng/uL). PicoGreen is specific for double
stranded DNA and provides an accurate measure of dou-
ble stranded DNA content. DNA fragment length was
measured by electrophoresis using 100 ng of DNA on pre-
cast 0.8% agarose gels (E-gel, Invitrogen) or for shorter,
amplified DNA samples, on 1.2% agarose gels. In all
instances 100 ng of each purified sample was loaded per
gel lane (based on PicoGreen quantitation) and com-
pared to an identical amount of a RocheGen DNA stand-
ard, with a known mass in the 100 kb–200 kb range. On
a 0.8% agarose gel assay, DNA fragments with a length
greater than about 40 kb will migrate as a single collapsed
band, which relative to a high molecular weight standard,
can be used to estimate the fraction of the unknown sam-
ple greater than about 40 kb. On a 1.2% agarose gel, DNA
fragments with a length greater than about 10 kb will
migrate as a single collapsed band, which is an estimate of
that fraction of the sample greater than 10 kb.
Whole Genome Amplification
Roughly 50% of the 5 uL–10 uL samples obtained from
Guthrie cards were concentrated enough for use in micro-
array analysis. 1 ng (about 0.5% of the purified DNA sam-
ple) from each sample, was subjected to whole genome
amplification using the Sigma-Rubicon PCR based tech-
nology, per the manufacturer's protocol (Sigma-Aldrich
Corporation) under CLIA control at Expression Analysis
(Raleigh-Durham NC). The resulting whole genome
amplified product was then diluted to 50 ng/uL and used
for Illumina 610 microarray analysis.
Illumina 610 Microarray Analysis
Eight specimens out of the full set of 24 were chosen for
microarray analysis (Table 1, underlined). The total DNA
yield (Table 1, second column) and average age of the 8
chosen (Table 1, last column) did not deviate significantly
Table 4: Primary DNA vs Whole Genome Amplified DNA Analyzed on Illumina 610 Microarrays
Sample1 Primary 
Isolate
Sample2 Whole 
Genome Amplified
No Call in one of 
the samples
No Call in Both 
Samples
Concordance Discordance Concordance 
Rate (%)
MOD 881 WGA 881 31221 981 559134 1156 99.79
MOD 892 WGA 892 18592 1098 572300 502 99.91
MOD 919 WGA 919 27450 990 563096 956 99.83
MOD 937 WGA 937 16551 1075 574418 448 99.92
MOD 920 WGA 920 27354 1425 562951 762 99.86
MOD 975 WGA 975 26404 1758 563599 731 99.87
MOD 986 WGA 986 22113 1410 568375 594 99.9
MOD 001 WGA 001 33998 1850 555479 1165 99.79
Concordance between sample pairs was determined by Illumina BeadArray analysis.Publish with BioMed Central    and   every 
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from the average of all 24. However, due to volume varia-
bility in the final concentrated DNA sample, the average
mass concentration of the 8 specimens chosen for micro-
array analysis (59 ng/uL) was approximately twice that of
the average over the entire set of twentyfour (26 ng/uL)
thereby matching or exceeding the DNA mass concentra-
tion (50 ng/uL) required for optimal Illumina 610 micro-
array performance: see for instance ref 16.
Two hundred nanograms of each sample were then ana-
lyzed by the microarray laboratories of Expression Analy-
sis (Raleigh-Durham NC). Briefly, all samples were
analyzed on the Illumina 610M microarray platform and
subjected to preliminary statistical analysis to generate a
SNP call rate, which is a standard metric used to assess
data quality. Both unamplified and Sigma-Rubicon whole
genome amplified samples were measured on the Illu-
mina 610 microarray platform and then additionally sub-
jected to pair-wise concordance analysis using standard
methods.
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